Evidence map›Paper›PMID 31745167›Full record

ArticleScientific reports2019

IL-25 exacerbates autoimmune aortitis in IL-1 receptor antagonist-deficient mice.

Takamichi Yoshizaki, Satoshi Itoh, Sachiko Yamaguchi, Takafumi Numata, Aya Nambu, Naoyuki Kimura, Hajime Suto, Ko Okumura, Katsuko Sudo, Atsushi Yamaguchi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. [EJNMMI research · 2023
    Article
  4. Animal models for large vessel vasculitis - The unmet need.Rheumatology and immunology research · 2023
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Takamichi YoshizakiLaboratory of Systems Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
Satoshi ItohDepartment of Cardiovascular Surgery, Saitama Medical Center, Jichi Medical University, Saitama, 330-8503, Japan.
Sachiko YamaguchiLaboratory of Systems Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
Takafumi NumataLaboratory of Systems Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
Aya NambuLaboratory of Systems Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.ORCID http://orcid.org/0000-0002-2797-6420
Naoyuki KimuraLaboratory of Systems Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
Hajime SutoAtopy Research Center, Juntendo University School of Medicine, Tokyo, 113-8412, Japan.
Ko OkumuraAtopy Research Center, Juntendo University School of Medicine, Tokyo, 113-8412, Japan.
Katsuko SudoAnimal Research Center, Tokyo Medical University, Tokyo, 160-8402, Japan.
Atsushi YamaguchiDepartment of Cardiovascular Surgery, Saitama Medical Center, Jichi Medical University, Saitama, 330-8503, Japan.
Susumu NakaeLaboratory of Systems Biology, Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan. snakae@ims.u-tokyo.ac.jp.
Jichi Medical University · JPJuntendo University · JPSystems Biology Institute · JPTokyo Medical University · JPJapan Science and Technology Agency · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IL-25, a member of the IL-17 family of cytokines, is known to enhance type 2 immune responses, but suppress type 3 (IL-17A)-mediated immune responses. Mice deficient in IL-1 receptor antagonist (Il1rn

Indexed as

AnimalsAortitisAutoimmune DiseasesDendritic CellsInterleukin-17Interleukin-1betaInterleukin 1 Receptor Antagonist ProteinInterleukinsMacrophagesMiceMice, Inbred BALB CMice, KnockoutNeutrophilsRNA, MessengerTumor Necrosis Factor-alphaIl17a protein, mouseIL1B protein, mouseIl1rn protein, mouseInterleukin-17Interleukin-1betaInterleukin 1 Receptor Antagonist ProteinInterleukinsMydgf protein, mouseRNA, MessengerTnf protein, mouseTumor Necrosis Factor-alpha

Identifiers

PMID31745167
PMCPMC6864066
OpenAlexW2990564113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.